Xcopri is owned by Sk Life.
Xcopri contains Cenobamate.
Xcopri has a total of 1 drug patent out of which 0 drug patents have expired.
Xcopri was authorised for market use on 10 March, 2020.
Xcopri is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Xcopri from March, 2024.
The generics of Xcopri are possible to be released after 30 October, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7598279||SK LIFE||Neurotherapeutic azole compounds|| |
(4 years from now)
|New Chemical Entity Exclusivity (NCE)||Mar 10, 2025|
NCE-1 date: March, 2024
Market Authorisation Date: 10 March, 2020
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic